Panama's own insurance regulator published the number. Through January 2026, private health insurance premiums grew 5.5% year over year, from US$49.1 million to US$51.8 million. Health claims paid grew more than twice as fast: up 13.1%, from US$29.5 million to US$33.4 million, according to the Superintendencia de Seguros y Reaseguros de Panama's comparative filing.
That gap is the whole story. Premium growth is the number insurers can price for. Claims growth outpacing it is the number that erodes margin quietly, month after month, until someone finally goes looking for where it is coming from.
Panama is also getting harder to hide in
Several things are converging on Panama's insurers right now, independent of any one company's strategy.
Panama is on track to be the first Latin American market to report insurance financials under NIIF 17 in 2026, according to Moody's Local Centroamerica's recent sectoral analysis cited by La Estrella de Panama. That means more granular data requirements and tighter coordination between actuarial, finance, and claims than the old reporting standard ever demanded. CFOs will not have a choice about visibility into their own numbers much longer.
The government is pushing in the same direction from the outside. MINSA is moving to formalize the country's health accounts entirely, pursuing a decree to build a systemwide, automated data-capture system after publicly acknowledging that Panama's financial health data has been fragmented, poorly standardized, and thin on private-sector input. The initiative is tied to the ministry's 2026-2035 national health strategy, and it has already been discussed directly with the insurance superintendency and private providers, not just drafted in isolation, according to MINSA.
There is also a live effort integrating MINSA and the Caja de Seguro Social around a single shared clinical record. As health director Carlos Abadia put it directly, the two institutions are actively working toward "una aplicacion unica del expediente clinico", a single clinical-record application spanning the entire public health system, replacing what has historically been separate record systems, according to Prensa.com.
And the cost side of the ledger is under its own documented pressure. MINSA's Law 528 expands access hours across the health system, and the ministry has said plainly that funding has not caught up: it budgeted US$3.503 billion for 2026 against US$3.887 billion requested, a US$384 million gap. MINSA has warned publicly that the expansion will need more payroll, more operating spend, and more medical supply than what is currently funded, according to Prensa.com.
Layer on top of that a new framework law mandating annual preventive screening for chronic disease: glucose, HbA1c, creatinine, lipid profile, and blood pressure. The claims pipeline is set to widen before anyone has fully caught up on what is already inside it. More screening finds more chronic conditions. More chronic conditions mean more prescriptions, more authorizations, more claims.
Panama's prescribing infrastructure is moving in the same direction. CSS's Mi Receta Digital program, which brings private-sector physicians into the national digital prescription system, had already registered around 250 private-sector doctor requests as of May 2026, according to CSS. That is early proof that the shift toward auditable, near-real-time prescription rails is underway, not just proposed.
The warning signs are already public
None of this is theoretical for Panama specifically. The country's own pharmacists have already gone on record about gaps in the national pharmacy control system. Reporting on CSS's SALMI platform, the system meant to manage medication logistics and dispensing across the public network, documents specialists flagging the absence of automated clinical alerts that would catch duplicate medications, incorrect doses, contraindications, or drug interactions before they reach the patient, according to La Estrella de Panama.
The same reporting notes that SIS and SALMI keep separate records, so medication availability can vary depending on which system a pharmacist checks. It also describes real cases of patients receiving duplicate antibiotic treatments from different physicians with no automatic flag, forcing pharmacists to manually call doctors to sort out which treatment should actually proceed.
That is the public system, documented in local press, describing gaps in the exact same basic function private insurers depend on to know where their pharmacy spend is actually going: tracking what gets prescribed against what gets dispensed. If a national system with full regulatory backing and institutional resources is still finding daylight between the two, it is a reasonable bet that private books, running the same prescribe-then-dispense chain with less centralized oversight, are not cleaner by default.
The pharmacy book is usually the blind spot
Here is what we have found holds true across Latin American health books broadly: in one Latin American claims analysis, 43.4% of pharmaceutical spend showed detectable anomalies, including waste, abuse, fraud, and clinically inappropriate approvals made without malice. On a 50,000-subscriber population, that worked out to US$5.1 million a year in one real book we analyzed.
The single largest piece of it was not fraud. It was branded drugs dispensed when a clinically equivalent generic was sitting right there: 71% of branded products had a generic alternative, under 5% were actually dispensed as generic, and 99.8% of those substitutions would have been clinically safe.
We are not saying that number is Panama's number. Every book is different. But the mechanism does not change by geography: pharmacy claims are evaluated one transaction at a time, while the patterns that actually cost money - early refills, same-molecule re-authorization, substitution economics, prescriber-level behavior - only become visible when you look at the sequence, not the single claim.
A market where claims are already outpacing premiums, where authorities are actively documenting their own control gaps, and where NIIF 17 is about to demand better data discipline anyway, is exactly the kind of market where that blind spot gets expensive.
If you are running a health book in Panama and want to know what is actually in yours, reach out to Inspector AI. We are happy to walk you through what that analysis could look like on your own claims.